How Leen Kawas Views Tariffs and Advanced Technologies as Key Drivers of Pharmaceutical Reshoring
The United States is witnessing a remarkable revival in domestic pharmaceutical production as manufacturers increasingly return operations to American soil after decades of offshoring. According to biotechnology expert Leen Kawas, this reshoring movement represents far more than an economic trend—it’s a critical step toward securing America’s medical supply chain and enhancing national healthcare resilience.
Recent trade policies have injected new momentum into pharmaceutical reshoring efforts. The administration has implemented broad tariffs affecting imports from various countries, specifically focusing on the pharmaceutical sector. While pharmaceuticals initially received exemptions from the “Liberation Day” tariffs, industry sources report that pharmaceutical-specific tariffs of “25% or higher” may soon be implemented, according to Fierce Pharma.
“The current administration’s tariff policies are accelerating decisions that many pharmaceutical companies were already considering,” says Leen Kawas. “Though tariffs create immediate challenges for companies with global supply chains, they simultaneously provide powerful incentives for investing in domestic manufacturing infrastructure.”
Industry experts note that these tariffs will likely stimulate increased investment in U.S. manufacturing facilities, though the transition will require time. According to Reuters, the Pharmaceutical Research and Manufacturers of America (PhRMA) has indicated it typically takes 5-10 years and approximately $2 billion to establish a new production facility in the United States, partly due to stringent regulatory requirements.
Major pharmaceutical companies have already announced substantial commitments to domestic manufacturing. Johnson & Johnson revealed plans for a $55 billion investment in U.S. manufacturing, research and development, and technology over the next four years. Eli Lilly similarly unveiled intentions to construct four manufacturing sites in the United States at a cost of at least $27 billion, with three facilities focused on producing active pharmaceutical ingredients—effectively bringing their small-molecule API production back to American soil.
Leen Kawas points out that these investments reflect a fundamental shift in industry perspective: “Leading pharmaceutical companies increasingly recognize that the benefits of domestic production—supply chain security, quality assurance, and intellectual property protection—outweigh the short-term cost advantages of overseas manufacturing.”
Beyond enhancing supply chain security, domestic pharmaceutical manufacturing yields additional benefits throughout the American economy. “Domestic pharmaceutical production creates high-quality jobs across the skill spectrum, from production line workers to specialized engineers and scientists,” notes Leen Kawas. “These positions support local economies and help rebuild America’s manufacturing foundation, which has experienced significant erosion over recent decades.”
The proximity of production facilities to research and development centers also promotes innovation by facilitating faster iteration and more efficient knowledge transfer, ultimately accelerating the development of new therapies. Environmental considerations provide another advantage: reduced transcontinental shipping minimizes the carbon footprint associated with pharmaceutical production and distribution.
Despite the compelling arguments for reshoring, significant challenges remain. According to Pharmaphorum, workforce development represents a critical obstacle. After decades of offshoring, many American communities lack the specialized skills required for pharmaceutical manufacturing. Addressing this skills gap necessitates investments in education, training programs, and partnerships between industry and academic institutions.
“We must recognize that reshoring isn’t simply about relocating final production steps to the United States,” explains Leen Kawas. “A comprehensive reshoring strategy requires developing local sources for raw materials and intermediate components. Otherwise, we’re merely shifting our vulnerabilities upstream in the supply chain.”
As reshoring efforts continue to gain momentum, America’s pharmaceutical supply chain is positioned for a transformative evolution—one promising greater security, resilience, and self-sufficiency. While the journey may be complex and gradual, Leen Kawas maintains that companies proactively investing in domestic manufacturing capabilities will be better equipped to navigate an increasingly unpredictable global landscape while securing America’s pharmaceutical future.
